Trials / Completed
CompletedNCT06494774
A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese Men
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Oral Doses Over 10 Days of BI 1815368 in Japanese Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability. pharmacokinetics (PK), and pharmacodynamics of BI 1815368 in healthy Japanese male subjects following administration of single rising doses or multiple doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1815368 | BI 1815368 |
| DRUG | Placebo matching BI 1815368 | Placebo matching BI 1815368 |
Timeline
- Start date
- 2024-08-19
- Primary completion
- 2024-11-13
- Completion
- 2024-11-13
- First posted
- 2024-07-10
- Last updated
- 2025-01-22
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT06494774. Inclusion in this directory is not an endorsement.